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Abstract
Background—Identifying and treating genital infections, including sexually transmitted 
infections (STI), among newly diagnosed human immunodeficiency virus (HIV)-infected 
individuals may benefit both public and individual health. We assessed prevalence of genital 
infections and their correlates among newly diagnosed HIV-infected individuals enrolling in HIV 
care services in Namibia.
Methods—Newly diagnosed HIV-infected adults entering HIV care at 2 health facilities in 
Windhoek, Namibia, were recruited from December 2012 to March 2014. Participants provided 
behavioral and clinical data including CD4+ T lymphocyte counts. Genital and blood specimens 
were tested for gonorrhea, Chlamydia, trichomoniasis, Mycoplasma genitalium, syphilis, bacterial 
vaginosis, and vulvovaginal candidiasis.
Results—Among 599 adults, 56% were women and 15% reported consistent use of condoms in 
the past 6 months. The most common infections were bacterial vaginosis (37.2%), trichomoniasis 
(34.6%) and Chlamydia (14.6%) in women and M. genitalium (11.4%) in men. Correlates for 
trichomoniasis included being female (adjusted relative risk, [aRR], 7.18; 95% confidence interval 
[CI], 4.07–12.65), higher education (aRR, 0.58; 95% CI, 0.38–0.89), and lower CD4 cell count 
(aRR, 1.61; 95% CI, 1.08–2.40). Being female (aRR, 2.39; 95% CI, 1.27–4.50), nonmarried (aRR, 
2.30; (95% CI, 1.28–4.14), and having condomless sex (aRR, 2.72; 95% CI, 1.06–7.00) were 
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independently associated with chlamydial infection. Across all infections, female (aRR, 2.31; 95% 
CI, 1.79–2.98), nonmarried participants (aRR, 1.29; 95% CI, 1.06–1.59), had higher risk to present 
with any STI, whereas pregnant women (aRR, 1.16, 95% CI 1.03–1.31) were at increased risk of 
any STI or reproductive tract infection.
Sexually transmitted infections (STIs) are well-established risk factors for acquisition and 
transmission of human immunodeficiency virus (HIV) infection.1,2 Bacterial and viral STIs 
are known to enhance the probability of HIV acquisition and transmission, through local 
genital tract inflammation that increases HIV shedding.3 Identifying and treating STIs in 
HIV-infected patients may therefore be an important prevention strategy. However, this 
approach is subject to considerable debate because the majority of randomized trials 
targeting STIs at the community level or among individuals at risk for HIV-1 infection have 
largely failed to demonstrate HIV prevention benefits from STI treatment.4
Although unresolved questions remain about the importance of STI treatment for HIV 
prevention, the World Health Organization (WHO) recommends that STI screening and 
treatment continue to be an integral part of comprehensive HIV strategies to improve the 
health of HIV-infected persons, their partners and families, and reduce the spread of HIV.5 
Treatment of curable STIs is also an essential part of primary health care and should be 
promoted in communities where the burden of STIs is substantial.4
The WHO recommends that health care workers ask newly diagnosed persons with HIV 
infection about STI symptoms and conduct laboratory screening for syphilis. When 
practical, women should also receive testing for gonorrhea and Chlamydia. Persons 
diagnosed with an STI should be treated, and treatment offered to their sexual partners. 
Etiologic approaches should be considered for persons who exhibit persistent or recurrent 
symptoms after initial treatment.5 However, it is unclear how often these directives are 
implemented in HIV care programs, especially in resource-limited settings.
Namibia, an upper middle income country with approximately 2.2 million people, has one of 
the largest income disparities in the world, with more than 38% living in poverty.6 With an 
estimated adult HIV prevalence of 14%7 in 2013, Namibia has one of the most severe HIV 
epidemics in Africa. In 2013, a Demographic Health Survey indicated 10% of women and 
6% of men reported having an STI in the past 12 months7; however, data on rates of genital 
infections among HIV-infected individuals attending HIV care and treatment clinics are not 
available.
To inform Namibia's HIV care and treatment program about the potential use of routine STI 
screening and treatment among HIV-infected persons, we conducted an STI etiologic survey 
in 2 HIV clinics in Windhoek, Namibia, to assess the burden of genital infections among 
newly diagnosed HIV-infected adults entering HIV care. Our main objectives were to 
estimate STI prevalence, quantify recent sexual risk behaviors, and identify corresponding 
risk factors in HIV-STI coinfected persons.
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Study Design, Eligibility and Study Procedures
From December 2012 to March 2014, HIV-infected adults attending HIV testing and 
counseling clinics at 2 health facilities in Windhoek were offered enrollment in a genital 
infection study. The clinics were located in Katutura and Okuryangava, historically 
disadvantaged urban and periurban townships on the outskirts of Windhoek. Consecutive 
patients were approached after receiving an HIV diagnosis and screened for inclusion in the 
study. Enrollment eligibility criteria included: HIV-positive status, not yet enrolled in HIV 
care or treatment, 18 years or older, and ability to provide informed consent to participate in 
the study. Women were excluded from enrollment if they were more than 36 weeks pregnant 
or less than 8 weeks postpartum.
At enrollment, participants were administered a structured questionnaire and underwent a 
physical examination to assess for genital infections. Genital infections were classified as 
STIs or as endogenous infections, not sexually transmitted, labeled as other reproductive 
tract infections (RTIs). Blood and genital specimens were collected for laboratory testing of 
genital infections and CD4 T-lymphocyte counts assessment. Patients reporting symptoms 
and/or with signs of genital infections at examination were treated by the study nurse 
according to Namibian Ministry of Health and Social Services (MOHSS) STI syndromic 
treatment guidelines.
Asymptomatic participants with positive laboratory tests were contacted and asked to return 
to the clinic to receive appropriate antimicrobial treatment. All participants treated for 
genital infections were given a referral card for their sexual partner(s) to seek STI care and 
HIV testing and counseling.
Specimens and Laboratory Testing
Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, 
Mycoplasma genitalium, and Treponema pallidum, was performed on all participants. Men 
provided first-catch urine specimens. Vaginal swabs were collected for molecular biology 
analysis and preparation of vaginal smears, and a urine sample for pregnancy testing. All 
participants had 5 mL of blood drawn on dry tube and 5 mL on ethylenediaminetetraacetic 
acid tube for syphilis serology and CD4 T-lymphocyte counts, respectively.
First-catch urine and vaginal swabs specimens were tested for C. trachomatis, N. 
gonorrhoeae, T. vaginalis, and M. genitalium by real-time multiplex polymerase chain 
reaction (M-PCR) assay and the Rotor-Gene 6000 instrument (Qiagen Inc., Valencia, 
Calif).8 Genital ulcer swabs were collected from participants presenting with genital ulcers 
and M-PCR was used to detect herpes simplex virus type 1 (HSV-1), HSV type 2 (HSV-2), 
T. pallidum, and C. trachomatis. The rapid plasma reagin assay was used to screen for 
syphilis and confirmation was performed using T. pallidum hemagglutination assays. 
Asymptomatic participants with positive rapid plasma reagin and T. pallidum 
hemagglutination assay results were categorized as having syphilis. Vaginal smears were 
prepared and evaluated for bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC). 
Gram-stained vaginal smear slides were examined for BV using Nugent scoring system.9 
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Scores of 0 to 3 represented normal vaginal flora, 4 to 6 represented abnormal flora, and 7 to 
10 were classified as BV. Vulvovaginal candidiasis was defined as the presence of budding 
yeast or pseudohyphae on Gram-stained vaginal smear along with self-reported genital 
itching and/or vaginal discharge on examination. Bacterial vaginosis and VVC were 
classified as RTIs not sexually transmitted and referred to as RTIs. CD4 counts were 
assessed using point-of-care CD4 analyzer (Alere PIMA CD4, Waltham, Mass). Human 
immunodeficiency virus testing was performed by government-supported clinics that follow 
the national HIV testing guidelines in Namibia.
Statistical Analysis
Data were captured on article forms by trained study nurses and a research assistant, and 
later double-entered into EpiInfo 7. Sexually transmitted infection prevalence was calculated 
for men and women, and prevalence differences between men and women and their 95% 
confidence intervals were computed. Associations between STI infection and sexual risk 
factors were calculated using Poisson regression.10 Robust Huber-White sandwich variance 
estimators were used to mitigate any clinic-specific cluster effect on variances. The 
following characteristics were evaluated as potential risk factors for genital infections: sex, 
age, marital status, education, employment status, sex partners during previous 6 months (≤1 
vs ≥2), number of sexual encounters with current partner during the previous 6 months, 
residence with last sex partner, having had sex during the past week, condom use during last 
sexual encounter, condom frequency with last partner, history of STIs, and CD4 count 
category. A separate analysis of risk factors was conducted among women to identify any 
possible associations between genital infections and pregnancy status. Potential correlates 
with P values ≤ 0.25 in bivariate associations were included in full multivariate models for 
each genital infection. Factors that were not at least marginally significant (P ≤ 0.10) were 
sequentially deleted to obtain final models. Statistical analyses were performed using 
STATAv.13.0 (StataCorp, College Station, Tex).
Ethical Considerations
The study was approved by the institutional review board of both the Namibian MOHSS and 
the US Centers for Disease Control and Prevention.
RESULTS
Study Population
Overall, 559 newly diagnosed HIV-infected participants were enrolled in the study. Of these, 
56% were women; the median age was 30 years (interquartile range, 25–35 years) among 
women and 35 years (interquartile range, 32–43 years) among men (Table 1). The 
distribution of education differed significantly by sex: males typically had lower levels of 
education. Men were more likely than women to be employed and married. Ninety-four 
participants (15.6%) reported using condoms consistently over the past 6 months; patterns of 
condom use differed significantly by sex (Table 1). Among those who reported only 1 
partner in the past 6 months, women (63%) were more likely to have had condomless sex 
than men (37%). The reverse was observed among those reporting 2 or more partners. At the 
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time of enrollment, 27% of women were pregnant. Women had significantly higher median 
CD4 counts compared with men.
Prevalence of STIs
Overall, 62.7%of women reported at least 1 symptom with vaginal discharge as the most 
common. Approximately 9.5% of women and 9.8% of men reported symptoms consistent 
with genital ulcers and only 1.5% of men reported symptoms of urethral discharge.
Among 335 women, 34.6%, 14.6%, 12.8%, and 4.5% had a diagnosis of trichomoniasis, 
Chlamydia, M. genitalium and gonorrhea, respectively (Table 2). For RTIs, the prevalence of 
BV and VVC was 37.2% and 18.2%, respectively (Table 2). About 32.5% of women had 2 
or more concurrent genital infections, including BV and VVC; 80% presented with at least 1 
RTI or STI. The 264 male participants in this study had distinctly lower prevalence of 
Chlamydia and trichomoniasis compared with women. Only 2.4%, 5.2%, and 11.4% had 
gonorrhea, Chlamydia and M. genitalium, respectively; 3.8% of men had multiple 
infections. The prevalence of syphilis was 4 times higher in men than in women (2.4% vs 
0.6%). Among participants presenting with genital ulcers, the prevalence of HSV-2 was 
33.3% and 47.8% among women and men, respectively. Two participants, who had a 
serologic diagnosis of syphilis, also had a diagnosis of Treponema pallidum in genital 
ulcers. No other ulcer-causing pathogen was identified. Prevalence of STIs or RTIs generally 
did differ with respect to pregnancy status among women. Pregnant women had a higher 
prevalence of STI/RTI especially for chlamydia (18.6 %vs 10.7%) and VVC (25%vs 14.9%) 
than nonpregnant women.
Correlates of STIs
We found significant behavioral and demographic correlates with laboratory-confirmed 
trichomoniasis, chlamydial infection, VVC, and any genital infection (Table 3). The risk of 
trichomoniasis was 7.18 times greater among females (95% confidence interval [CI], 4.07–
12.65) compared to males, and the risk was 1.61 time greater among those with CD4 < 200 
cells/µL than among those with CD4 > 500 cells/µL. Female participants (adjusted relative 
risk [aRR], 2.39; 95% CI 1.27–4.50), nonmarried participants (aRR, 2.30; 95% CI, 1.28–
4.14) and those who reported never using condoms (aRR, 2.72; 95% CI, 1.06–7.00) were 
more likely to present with Chlamydia. Single women (aRR, 1.63; 95% CI, 1.01–2.66), 
women with CD4 count ≤ 200 cells/µL (aRR, 2.05; 95% CI, 1.07–3.93), and women with 
vaginal discharge (aRR, 1.86; 95% CI, 1.06–3.27) had an elevated risk of VVC. Across all 
STIs excluding HSV-2, after adjusting for sex, nonmarried participants were 1.29 (95% CI, 
1.06–1.59) times more likely to have multiple infections than participants who were married 
or cohabiting. After adjusting for sex, the risk of infection with any RTI or STI was 1.22 
(95% CI, 1.07–1.41) times greater for nonmarried participants versus those who were 
married or cohabiting. Pregnant women had an elevated risk of presenting with chlamydia 
(aRR, 1.90; 95% CI, 1.07–3.39), VVC (aRR, 1.93; 95% CI 1.15–3.23), and any RTI or STI 
(aRR, 1.16; 95% CI, 1.3–1.31), excluding HSV-2.
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This is the first report of etiological data among adults newly diagnosed with HIV infection 
at health facilities in 2 large townships in Windhoek, Namibia. Overall, the prevalence of 
vaginal infections was high, especially in pregnant women. Approximately 37.2%, 34.6%, 
and 18.2% of women had laboratory confirmed BV, trichomoniasis, and VVC, respectively. 
The prevalence of other STIs, such as Chlamydia, M. genitalium, and gonorrhea, was lower.
These results are consistent with other sub-Saharan African studies where similar rates of 
genital infections were reported among HIV-infected pregnant and nonpregnant 
women.11–15 The risk of individual infection showed in a multivariate model that pregnancy 
was associated with higher risk of chlamydia, VVC, and any STI or RTI.
The highest prevalence of coinfections HIV/STI occurs among individuals newly diagnosed 
with HIV.16 Similarly, studies of persons who tested HIV positive at the time of STI testing 
found a mean point prevalence of 16.3%,17 reflecting the importance STIs may play as 
reliable markers for HIV transmission.
Although the existence of higher STI prevalence among HIV-infected individuals is well 
established,17 our findings are contextually important for the Namibian MOHSS. Our results 
will help the MOHSS not only to plan and procure drugs and other commodities for HIV 
and STI/RTIs but also to develop public health messaging and communication strategies 
about STI, safer sex practices, and positive prevention.
Similar to other studies of HIV-infected women,16,18,19 trichomoniasis had the highest 
prevalence in our study. Trichomoniasis, the second most common STI in the world,20 is 
also known to be more prevalent in HIV-positive women21 and is associated with significant 
morbidity, including pelvic inflammatory disease, cervical dysplasia, and adverse 
reproductive health outcomes.22 Although women were disproportionately affected by 
trichomoniasis in this study, any public health approach to control trichomoniasis among 
women should also address the role of men in transmission, because up to 77% of 
trichomoniasis is asymptomatic in men23 and those may represent critical sources of 
infection and reinfection in women.
Bacterial infections such as gonorrhea, Chlamydia and M. genitalium accounted for a group 
of genital infections with the second highest prevalence in this study. Rates of gonorrhea and 
Chlamydia were significantly higher in women compared with men. Furthermore, the 
prevalence of Chlamydia was significantly higher in pregnant women compared with 
nonpregnant women. Pregnant women tended to be younger, which may have severe 
implications for reproductive health outcomes, such as infertility, chronic pelvic or rectal 
pain, increased risk of ectopic pregnancy, and spontaneous abortion.20 Approximately 62% 
of women reported vaginal discharge, whereas 80% of women had laboratory confirmation 
of any STI or RTI, excluding HSV-2. This indicates a relatively high frequency of 
asymptomatic infections. Those asymptomatic infections may severely impact the 
effectiveness of syndromic case management, thus significantly impeding disease control. In 
this study, condomless sex was independently associated with chlamydial infection among 
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men and women, indicating that a behavioral intervention may also be needed for effective 
Chlamydia control efforts.
M. genitalium was the most prevalent genital infection among men, with a similar rate of 
infection identified among women. M. genitalium remains an important cause of urethritis in 
men and a likely cause of cervicitis and endometritis in women24,25 and is associated with 
genital HIV shedding,26 thus potentially intensifying the risk of HIV transmission. Men 
were more likely to have multiple sex partners yet had lower STI rates compared with 
women. Because sexual behavior was self-reported, it is possible that women were not 
truthful about the number of partners because of social desirability. Men had significantly 
lower CD4 counts at entry into HIV care. A study reporting on the distribution of CD4 
counts and viral load among antiretroviral naive, first time testers in South Africa concluded 
that HIV-infected men at their first HIV diagnosis were more likely to have lower CD4 
counts and higher viral loads. This may be due to the fact that women may have earlier 
opportunity to engage with HIV testing through antenatal care or prevention of mother to 
child transmission.
Age was intrinsically confounded with sex in the data, with little overlap between age ranges 
for men and women. However, univariate and multivariable analyses provided no evidence 
of associations between age and any of the STIs, including chlamydial infection or 
trichomoniasis, which are classically associated with younger age.13,27 Regardless, age 
cannot be eliminated as a risk factor in this population because age is confounded with sex, 
and the age ranges were narrow and excluded adolescents and young adults (Table 1).
The HSV-2 infection was measured only in the small sample of participants who presented 
with genital ulcers. This likely is an underestimation of prevalent herpes infection as we did 
not test for HSV-2 antibodies because of limited funding. Genital ulcers may not be noted in 
routine enrollment into HIV care without examination or questions regarding genital 
wounds. We wanted to explore how feasible WHO recommendation of episodic acyclovir 
treatment to accelerate healing and decrease HIV shedding in ulcers5 would be in the field. 
To date, no completely effective interventions are available for HSV-2 to complement 
primary prevention, such as condoms and fewer sex partners.
Our assessment was conducted in 2 clinics located in 2 townships in the northern outskirts of 
the capital city which includes large communities living in informal settlements. Residents 
of these townships come from all over Namibia and are often transient.6 However, our 
results are not generalizable to the entire population of persons newly diagnosed with HIV in 
Namibia.
In summary, women entering HIV care in these 2 HIV clinics in Namibia are substantially 
affected by prevalent genital infections. Given the relatively high prevalence of curable 
genital infections in our study, promotion and implementation of STI screening and 
treatment along with partner management strategies may be beneficial at entry into HIV care 
in Namibia.
One pivotal goal of our study was to build capacity in improving screening of genital 
infections at the national level. Although the startup cost of molecular diagnosis for genital 
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infections is initially higher, it is offset by its efficiency. Diagnosis timeliness and accuracy 
are enhanced, with the ability of processing multiple specimens and diagnosing multiple 
pathogens using a single specimen. Capacity building before, during, and after the study 
materialized through training of laboratory technicians in PCR techniques and good 
laboratory practice for ownership, laboratory equipment donation (M-PCR platform), 
procurement of reagents and implementation of quality control systems and standard 
operating procedures for sustainability.
Because of the relatively high prevalence of vaginal infections, such as BV and VVC, it is 
critical to emphasize approaches to increase women's awareness of urogenital symptoms 
with health care provider's proactive inquiry of genital symptoms and appropriate 
treatment.28
We unexpectedly found a pregnancy rate of 27% among newly HIV diagnosed women in 
these HIV counseling and testing clinics. This reinforces continuing vigilance for referral to 
reproductive health services from point of diagnosis, for safer pregnancy counseling and for 
referral to antenatal care and HIV prevention of mother-to-child transmission. The Namibian 
MOHSS has been strengthening integration and linkage to those services.
Based on the rates of trichomoniasis found in this study, implementation of primary and 
secondary prevention that include at least annual laboratory-based screening for 
trichomoniasis and other vaginal infections and prompt treatment19,29 may be warranted to 
reduce morbidity, improve quality of life, and decrease HIV genital shedding associated with 
the risk of HIV transmission. These strategies should be coupled with aggressive partner 
notification and management. A substantial number of infections with T. vaginalis may be 
asymptomatic, and repeat infections appear to be remarkably high among both HIV-positive 
and HIV-negative women in other settings.30 This underscores the critical need for the 
development and routine use of affordable point-of-care STI diagnostics for resource-
constrained settings where laboratory capacity is often lacking.
It is also desirable that active and frequent Chlamydia screening and treatment with partner 
management strategies be performed in this population. These strategies are crucial to 
reduce repeat infections and adverse outcomes, decrease genital shedding, and suppress 
inflammation associated with the risk of HIV transmission. Because condomless sex was 
associated with chlamydial infection in our study, it is vital to target this population for 
intensive risk reduction and promotion and provision of commodities such as male and 
female condoms for safer sex practices. Lastly, this etiologic assessment among adults 
recently diagnosed with HIV infection provides evidence that STI screening and treatment 
would be beneficial if promoted and systematically implemented at entry in HIV care 
services in Namibia.
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TABLE 1
Sociodemographic, Sexual Behavior and Clinical Characteristics of Newly Diagnosed HIV-infected Adults 
Entering HIV Care in Windhoek, Namibia
Variable Males Females Total P*
Total, n (%) 264 (44%) 335 (56%) 599
Age, median (IQR) 35 (32–43) 30 (25–35) <0.01
  Nonpregnant 31 (26–36) 228
  Pregnant 27 (24–32) 89 <0.01†
Education Level, n (% row) <0.01
  No education 24 (80%) 6 (20%) 30
  Col % (9%) (2%)
  Primary level 93 (55%) 77 (45%) 170
  Col % (36%) (23%)
  Secondary level 121 (36%) 218 (64%) 339
  Col % (44%) (66%)
  Postsecondary 3 (16%) 16 (84%) 19
  Col % (3%) (4%)
Unknown 23 (56%) 18 (44%) 41
Col % (8%) (4%)
Employment status,‡ n (%) <0.01
Employed 228 (55%) 188 (45%) 416
  Marital status,§ n (% row) <0.01
  Married 32 (62%) 20 (38%) 52
  Col % (17%) (7%)
  Cohabiting 106 (49%) 112 (51%) 218
  Col % (41%) (31%)
  Single/divorced/widowed 122 (38%) 203 (62%) 325
  Col % (41%) (62%)
Reported number of sex partners with no condom usage in the past 6 mo,¶ n (%) <0.01
  0 39 (41%) 55 (59%) 94
  Col % (15%) (16%)
  1 138 (37%) 232 (63%) 370
  Col % (52%) (69%)
  2–5 48 (74%) 17 (26%) 65
  Col % (18%) (5%)
> 5 3 (75%) 1 (25%) 4
  Col % (1%) (<1%)
  Unknown 36 (55%) 30 (45%) 66
  Col % (14%) (%9)
Pregnancy
  No — 228 (68%)
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Variable Males Females Total P*
  Yes — 89 (27%)
  No test result 18 (5%)
CD4 count, median (IQR) 248 (150–359) 318 (208–457) <0.01
*
Based upon the Pearson χ2 statistic except as noted.
†
Based upon the 2-sample Wilcoxon rank-sum test.
‡
Excludes 2 men and 2 women who did not report status.
§
Excludes 4 men who did not report status.
¶
Excludes 36 men and 30 women who did not report status.
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